The discovery of ‘targeted’ drugs such as erlotinib, that blocks aberrant EGFR signaling in patient with mutant EGFR, and crizotinib that blocks ALK signaling in patients expressing the EML4-ALK driver fusion protein, has led to improvements in NSCLC therapy for a small population of patients. Here, EGFR is linked to non-small cell lung carcinoma.